Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
This rule finalizes and codifies the Medicare Drug Price Negotiation Program ("Negotiation Program") and establishes certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program ("Part D Program") as required by the Inflation Reduction Act of 2022. This final rule also finalizes a proposed policy for specific fixed combination drugs that are new formulations.
Related coverage
- Marine Mammals; Incidental Take During Specified Activities; Proposed Incidental Harassment Authorization for Southwest Alaska Stock of Northern Sea Otters in Kodiak, Alaska
- Employee or Independent Contractor Status Under the Fair Labor Standards Act, Family and Medical Leave Act, and Migrant and Seasonal Agricultural Worker Protection Act
- Administrative Disaster Declaration of a Rural Area for the State of New Hampshire
- Administrative Declaration of a Disaster for the Territory of Guam
- Miscellaneous Technical Amendments; Technical Amendment
- Extension of Import Restrictions Imposed on Archaeological and Ethnological Material of Egypt